City of Sugar Land Awards $1 Million Incentive to Support Hope Biosciences Expansion
The investment further enhances Sugar Land as a hub for life sciences and innovation
SUGAR LAND, Texas (Jan. 6, 2026) – The City of Sugar Land has approved a $1 million performance-based incentive to support the expansion of Hope Biosciences, a leading Sugar Land-based biopharmaceutical company specializing in adult stem cell-based therapeutics.
As part of its growth strategy, Hope Biosciences recently purchased its existing facility at 16700 Creek Bend Drive, securing a permanent home in Sugar Land. The company will invest an additional $2 million in building improvements and equipment and create 15 new jobs over the next five years with an average annual salary of $61,240.
The incentive provided through the Sugar Land Office of Economic Development & Tourism, will be distributed over five years at $200,000 annually. The agreement helps ensure the retention of a growing, federally recognized biopharmaceutical operation with a Regenerative Medicine Advanced Therapy (RMAT) designation and enables facility improvements that expand long-term manufacturing capacity.
“Hope Biosciences is a homegrown success story and a key example of how life science companies can thrive in Sugar Land,” said Jennifer Alexander, Business Development Manager. “This incentive marks the first granted to a life sciences company and signals our commitment to supporting this sector, which is critical to our city’s economic future.”
Founded in Sugar Land, Hope Biosciences develops groundbreaking therapies using stem cells derived from a patient’s own body to regenerate or repair damaged tissues and treat conditions including neurodegenerative and autoimmune diseases. The company operates a Good Manufacturing Practice (GMP)-compliant manufacturing facility and is the only company in the United States offering clinical-grade stem cell banking for both adults and newborns.
Hope Biosciences is advancing multiple FDA-authorized clinical trials for diseases such as multiple sclerosis, lupus, and traumatic brain injury, including two Department of Defense-backed clinical trials. In addition to clinical research, the company partners with regional and national institutions and provides direct-to-consumer stem cell banking services.
“Use of Hope Biosciences’ technology continues to grow significantly, but it all started here,” says Donna Chang, CEO, Hope Biosciences. “The city has supported us at every stage, and their continued commitment reinforces our deeply held belief that Sugar Land is the ideal place to grow a company like ours. We see vibrant expansion in the world of cell and gene therapy, and Sugar Land has all the elements to attract more companies pursuing innovative work. Hope Bio’s progress is only the beginning for this industry, in this community. We are excited and grateful to be here.”
By supporting this expansion, Sugar Land strengthens its position as a hub for life sciences, sending a clear message to the industry that the City is committed to cultivating high-quality, innovation-driven companies.
About the City of Sugar Land
WE ARE TRAILBLAZERS ... relentless in our pursuit of progress so that our employees, residents, and businesses can enjoy a life better than they ever imagined. Sugar Land has always been a city that surpasses expectations, fearlessly forging new paths while delivering top-tier services to its residents. According to our latest Citizen Satisfaction Survey, 95 percent of residents love calling Sugar Land home, with 10 percent saying that nothing could make their lives better than they already are. As a community built on entrepreneurial spirit and a commitment to the future, we aim to be a city that the private sector looks to for inspiration. We don’t just follow trends—we set them. With unwavering determination, we are trailblazing a path toward a vibrant future where innovation and progress thrive. The possibilities are endless. Together, we can ensure a bright future for Sugar Land.
About the City of Sugar Land Office of Economic Development, Tourism, (SLOEDT) and Department of Redevelopment
The Sugar Land Office of Economic Development and Tourism (SLOEDT), a department of the City of Sugar Land, is committed to promoting sustainable economic growth and a vibrant visitor economy. Through its two divisions: Business Development and Tourism, SLOEDT focuses on attracting new businesses, retaining existing employers, revitalizing the community, implementing strategic initiatives, and fostering tourism. These efforts play a vital role in enhancing the quality of life for residents, supporting local businesses, and welcoming visitors.
Working alongside SLOEDT, the Department of Redevelopment plays a key role in strengthening Sugar Land’s economic future. With a mission to advocate for and support development and redevelopment that sustain strong community services and a thriving quality of life, the department facilitates strategic public-private partnerships and implements reinvestment and redevelopment strategies that bolster the city’s long-term fiscal health.
Together, these departments support a unified vision for prosperity and growth. For more information, visit www.SugarLandEcoDev.com or contact ecodev@sugarlandtx.gov.
About Hope Biosciences
Hope Biosciences, headquartered in Sugar Land, TX, is a leading cGMP compliant biopharmaceutical research and manufacturing company delivering safe, effective, and affordable stem cell solutions for degenerative and chronic conditions, and is the only clinical-grade facility in the nation offering private banking services for both adults and newborns from around the world.
Hope Bio uses proprietary technology to culture and expand mesenchymal stem cells, a type of adult stem cell found in many tissues in the body and in the placenta of newborns, to unprecedented volume and levels of viability. To date, Hope Bio’s cells have been put to work in nearly 50 FDA-authorized protocols for conditions and diseases currently considered “incurable” and affecting substantial portions of the American population, including two Department of Defense-supported clinical trials.